Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $24.77

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned a consensus rating of “Hold” from the twenty-five analysts that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $24.7727.

SRPT has been the topic of a number of recent analyst reports. Mizuho increased their target price on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Loop Capital set a $25.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Royal Bank Of Canada raised their price objective on Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a report on Tuesday, April 7th. Oppenheimer reissued an “outperform” rating and issued a $37.00 target price on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Finally, HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th.

Sarepta Therapeutics Price Performance

SRPT stock opened at $17.12 on Wednesday. The business has a 50 day moving average price of $18.93 and a 200 day moving average price of $19.69. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -17.81, a PEG ratio of 0.17 and a beta of 0.21. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. The company had revenue of $730.80 million for the quarter, compared to analysts’ expectations of $474.16 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the company earned ($3.42) earnings per share. Equities research analysts anticipate that Sarepta Therapeutics will post 3.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently modified their holdings of the company. Aberdeen Group plc grew its position in Sarepta Therapeutics by 59.6% during the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock worth $38,208,000 after purchasing an additional 740,360 shares during the last quarter. Mirador Capital Partners LP purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $3,012,000. Boxer Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 900.0% in the third quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company’s stock valued at $4,818,000 after buying an additional 225,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Sarepta Therapeutics by 143.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 106,759 shares of the biotechnology company’s stock worth $2,410,000 after buying an additional 62,981 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in shares of Sarepta Therapeutics by 109.1% during the third quarter. Principal Financial Group Inc. now owns 468,067 shares of the biotechnology company’s stock worth $9,020,000 after buying an additional 244,181 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.